Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
Francis BerenbaumRichard LangfordSerge PerrotKenji MikiFrancisco J BlancoTakaharu YamabeNaoki IsogawaRod JunorWilliam CareyLars ViktrupChristine R WestMark T BrownKenneth M VerburgPublished in: European journal of pain (London, England) (2021)
This exploratory analysis of data from a placebo-controlled, Phase 3 study of patients with moderate-to-severe osteoarthritis of the hip or knee for whom standard analgesics were not effective or could not be taken, found that onset of efficacy of subcutaneous tanezumab was within the first week, and efficacy was maintained through the 24-week treatment period. Tanezumab was effective in those patients with the most radiologically severe osteoarthritis.
Keyphrases
- placebo controlled
- knee osteoarthritis
- double blind
- rheumatoid arthritis
- early onset
- chronic pain
- phase ii
- study protocol
- total knee arthroplasty
- phase iii
- pain management
- open label
- high intensity
- randomized controlled trial
- big data
- drug induced
- machine learning
- squamous cell carcinoma
- postoperative pain
- total hip arthroplasty
- combination therapy
- artificial intelligence
- spinal cord
- replacement therapy